Innovative Medicines Initiative (IMI)

Iniciativa de Medicamentos Innovadores (IMI) 7º Programa Marco


IMI 8th Call 2012

  • New! Updated version of the indicative Call text  (version of 7 December 2012)     Notes for applicants:      – This latest version of the Call text is still indicative and subject to change, pending approval by the IMI Governing Board.      – The third topic (on chronic obstructive pulmonary disease / COPD) of the Taxonomy theme will not be launched under the 8th Call for proposals. However, IMI hopes to be able to include it in a future Call.      – As the timelines for the 8th Call will be tight, potential applicants are encouraged to start preparing consortia in response to the Call topics as soon as possible.
  • Sign up for the 8th Call webinars

Topics under consideration under the IMI programme ‘Combating Antibiotic Resistance: New Drugs for Bad Bugs (ND4BB)’ *

  • Topic 1C: Innovative Trial Design & Clinical Development (work package 6 of Topic 1)
  • Topic 3: Discovery and development of new drugs combating Gram – negative infections

*ND4BB (‘New Drugs for Bad Bugs’) represents a core element of the Action plan against the rising threats from Antimicrobial Resistance adopted by the European Commission as an answer to the Council Conclusions and the European Parliament resolution to establish an EU-wide plan to combat antimicrobial resistance. The ND4BB programme started in IMI’s 6th Call launched in May 2012 with two topics, and further topics are under consideration.

Topics under consideration under the Theme ‘Developing an aetiology-based taxonomy for human diseases’

  • Topic A: Approaches to develop a new classification for Systemic Lupus Erythematosus (SLE) and related connective tissue disorders and Rheumatoid Arthritis (RA)
  • Topic B: Approaches to develop a new classification for neurodegenerative disorders with a focus on Alzheimer’s disease (AD) and Parkinson’s disease (PD)



Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

Aviso de cookies